|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we set out to investigate cross-sectional and longitudinal disease effects in the upper cervical spinal cord in patients with ALS, progressive muscular atrophy (PMA: primarily lower motor neuron involvement) and primary lateral sclerosis (PLS: primarily upper motor neuron involvement), and their relation to disease severity and grey and white matter brain measurements.
|
31499409 |
2019 |
|
Anemia, Sickle Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
The iron depletion and the sickling of erythrocytes could be identified by Raman spectroscopy and a spectral model based on PLS accurately discriminated these IDA and SCD samples from the normal HbA.
|
31637552 |
2019 |
|
Congenital macroglossia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> To the best of our knowledge, this is the first report of macroglossia in PLS.
|
31307259 |
2019 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report the time course of CatC and CysF expression and describe the symptoms in a mouse experimental autoimmune encephalomyelitis (EAE) model using CatC knockdown (KD) and CatC over-expression (OE) mice.
|
30152001 |
2019 |
|
Macroglossia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> To the best of our knowledge, this is the first report of macroglossia in PLS.
|
31307259 |
2019 |
|
Lateral Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we set out to investigate cross-sectional and longitudinal disease effects in the upper cervical spinal cord in patients with ALS, progressive muscular atrophy (PMA: primarily lower motor neuron involvement) and primary lateral sclerosis (PLS: primarily upper motor neuron involvement), and their relation to disease severity and grey and white matter brain measurements.
|
31499409 |
2019 |
|
Iron deficiency anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The iron depletion and the sickling of erythrocytes could be identified by Raman spectroscopy and a spectral model based on PLS accurately discriminated these IDA and SCD samples from the normal HbA.
|
31637552 |
2019 |
|
Alpers Syndrome (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
PLS is associated with considerable cerebellar white and grey matter degeneration and the extra-motor profile of PLS includes marked insular, inferior frontal and left pars opercularis pathology.
|
31325016 |
2019 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abrogation of cathepsin C by Helicobacter pylori impairs neutrophil activation to promote gastric infection.
|
30596522 |
2019 |
|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
It gave an Area Under Curve (AUC) of 87.75% by the IDF and 85.12% by HMS MetS diagnosis criteria, higher than previous models.
|
31731612 |
2019 |
|
neurological disability
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
PLS-SEM analysis was conducted to identify factors which influence a young person with a physical and/or neurological disability's journey to work.
|
31503503 |
2019 |
|
Infection caused by Helicobacter pylori
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, CtsC expression in gastric epithelial cells and its role in Helicobacter pylori infection remain unclear.
|
30596522 |
2019 |
|
Progressive Muscular Atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we set out to investigate cross-sectional and longitudinal disease effects in the upper cervical spinal cord in patients with ALS, progressive muscular atrophy (PMA: primarily lower motor neuron involvement) and primary lateral sclerosis (PLS: primarily upper motor neuron involvement), and their relation to disease severity and grey and white matter brain measurements.
|
31499409 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge, this is the first study to report that DPPI expression and activation promotes the inflammation that enhances myocyte apoptosis and contributes to the adverse cardiac remodeling that subsequently leads to DCM.
|
31829530 |
2019 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three algorithms, Partial Least Squares-Discriminant Analysis (PLS-DA), Support Vector Machine (SVM), and eXtreme Gradient Boosting (XGBoost), were used to develop models to distinguish ASD from typically developing (TD) children and to detect potential biomarkers.
|
31114480 |
2019 |
|
PAROXYSMAL EXTREME PAIN DISORDER
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
According to transcriptional and physiological analyses in this study, the mprA/B and pepD signal transduction system was first proved to be presented and activated in Streptomyces albulus M-Z18 by pH shock, which positively regulated the transcription of ε-PL synthetase (Pls) gene and enhanced the Pls activity during fermentation.
|
31595454 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
R-PALS, L-PALS and combined R-PALS and L-PALS are important factors associated with AF recurrence following RFA in patients with CLD.
|
29460463 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Significantly, bioinformatic analyses show that CCL3 is related to type 1 diabetes, PLAGL1 to cardiomyocytes, and CTSC to albuminuria in type 2 diabetes.
|
30098304 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results of this study indicated that the composition of lipid species including diacyl phosphatidylethanolamine (dPE) (16:0/18:2, 18:0/18:2, 16:0/22:6, 18:0/20:4, and 18:0/22:6), 18:2 lysoPC (LPC), and ceramide (N22:0 and N24:1) was significantly altered in SLE patients with <i>p</i> < 0.05 and variable importance of the projection (VIP) > 1 in partial least squares-discriminate analysis (PLS-DA).
|
30282943 |
2018 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
|
28905990 |
2018 |
|
Motor symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study.
|
29779681 |
2018 |
|
Autoimmune vasculitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis.
|
29925593 |
2018 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
By using the multivariate regression models N-PLS (Partial Least Squares) and MORE (Multi-Omics REgulation) methodologies, we assessed the contribution of histone marks and transcription factors to the regulation of gene expression in the YMC.
|
30555512 |
2018 |
|
Granulomatosis with polyangiitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that pharmacological inhibition of CatC provides an effective measure to reduce PR3<sup>m</sup> and therefore has implications as a novel therapeutic approach in granulomatosis with polyangiitis.
|
29925593 |
2018 |
|
Mantle cell lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using in vitro screening, we discovered that the combination of PLS-123 and the mammalian target of rapamycin (mTOR) inhibitor everolimus exert synergistic activity in attenuating proliferation and motility of MCL cell lines.
|
28905990 |
2018 |